Hidradenitis Suppurativa in Pediatric Patients
Overview
Affiliations
Interest in and research on hidradenitis suppurativa (HS) have increased during the past decade, resulting in expanded knowledge about associated comorbidities and treatment efficacy. Knowledge about pediatric-onset HS is still limited, based on case studies, small case series, and extrapolation from adult studies. With increasing prevalence of childhood obesity, decreasing pubertal age, and increasing awareness of HS, physicians may start encountering younger HS patients. This review presents an updated discussion on the epidemiology, pathophysiology, and associated comorbidities in HS, with a focus on pediatric and adolescent patients. It also suggests recommendations for investigation and treatment based on current evidence.
Brown N, Kumassah P, Brown G, Brookmann S, Ambe P, Agbedinu K BMC Surg. 2025; 25(1):36.
PMID: 39849423 PMC: 11755844. DOI: 10.1186/s12893-024-02686-8.
Raudonis T, Sakaityte A, Vileikis T, Cernel V, Ganceviciene R, Zouboulis C Healthcare (Basel). 2024; 12(18).
PMID: 39337190 PMC: 11431364. DOI: 10.3390/healthcare12181849.
Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review.
Mendes-Bastos P, Benhadou F, Venturini M, Molina-Levya A, Thomas N, Alarcon I Front Med (Lausanne). 2024; 11:1403455.
PMID: 39040895 PMC: 11261743. DOI: 10.3389/fmed.2024.1403455.
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study.
Martora F, Marasca C, Cacciapuoti S, Fariello F, Potestio L, Battista T Clin Cosmet Investig Dermatol. 2024; 17:159-166.
PMID: 38283798 PMC: 10821645. DOI: 10.2147/CCID.S449367.
Atherton K, Shope C, Andrews L, Robinson-Pirotte I, Lee L, Cotton C Pediatr Dermatol. 2023; 41(1):28-33.
PMID: 38018236 PMC: 10842160. DOI: 10.1111/pde.15466.